Paul Hastings Advises Underwriters on Corvus Pharmaceuticals’ Underwritten Public Offering

Paul Hastings LLP advised Jefferies and Goldman Sachs & Co. LLC as lead book-running managers, for Corvus Pharmaceuticals Inc.’s (Nasdaq: CRVS) public offering of 7,900,677 shares of its common stock at a public offering price of $22.15 per share. Gross proceeds to Corvus Pharmaceuticals from the offering are expected to be approximately $175 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Corvus Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 1,185,101 shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about Jan. 23, 2026, subject to customary closing conditions.

Equity Capital Markets and Corporate Life Sciences chair Seo Salimi led the Paul Hastings team, which included of counsel Ryan Brewer and associates Michelle Sidle and Adam Swank.

About Paul Hastings
With widely recognized elite teams across 17 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers and corporations.